Dingkang Pharmaceutical

What Dingkang Pharmaceutical does

Dingkang Pharmaceutical Co., Ltd is a Shanghai-headquartered pharmaceutical company that imports and distributes Active Pharmaceutical Ingredients (APIs) to more than 600 domestic Chinese pharmaceutical manufacturers. Founded in the 1990s and operating from Room 310-312, Building 11, Maiduo Plaza on Lianhua South Road, the company functions as a regulated bridge between international API producers—primarily in India (Divis, IPCA, Piramal, Ami Lifescience, Virupaksha), with additional sourcing from France, Japan, Israel, and South Korea—and Chinese formulation enterprises. Beyond trading, Dingkang offers a professional drug registration service that handles dossier preparation, regulatory submission, and eCTD V4.0 compliance for both domestic and international clients navigating NMPA approval.

The product catalog spans cardiovascular APIs (Amlodipine Besylate, Atenolol, Bisoprolol Fumarate, Valsartan, Metoprolol Tartrate), antihistamines (Desloratadine), anti-inflammatory and analgesic agents (Nabumetone), antifungals (Fluconazole, Ketoconazole), neurological APIs (Levetiracetam, Quetiapine Fumarate), and emerging categories including weight management (Orlistat) and sleep health (Lemaitamide). Every API carries CDMF registration and is backed by USDMF and CEP certifications. Revenue is generated primarily through transaction-fee margins on API trading, with professional services fees from drug registration engagements as a secondary stream. Distribution is conducted directly via three regional sales departments covering all Chinese provinces and a separate Import/Export Business Department for international accounts, without reliance on third-party resellers.

Strategically, Dingkang positions itself on regulatory compliance depth, exclusive representation of major Indian API brands, and a multi-decade sales and registration talent base. Recent activity includes launches timed to major patent cliffs (Valsartan following Entresto expiry) and entry into consumer-adjacent verticals such as weight management and sleep health. The company is privately held with 251-500 employees, founder-led ownership, no disclosed institutional investors, no public funding rounds, and active participation in CPHI China (booth W3E26), CPHI Milan, CPHI India, and API China exhibitions as its primary demand-generation channel.

Name

Dingkang Pharmaceutical

Legal name

Dingkang Pharmaceutical Co., Ltd

Website

https://dingkang.com.cn

Company type

Private

Founded year

2003

Operating status

Operating

Headcount range

251–500 employees

Short description

Dingkang Pharmaceutical is a Shanghai-based API distributor serving 600+ Chinese pharmaceutical manufacturers, sourcing Active Pharmaceutical Ingredients from India, France, Japan, and South Korea, with value-added drug registration and eCTD submission services.

Ownership category

akta.pro rank

Product category

Pharmaceutical API Distribution

NAICS

Drugs and Druggists' Sundries Merchant Wholesalers (42421)

SIC

Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Pharmacy Benefit/Channel Services (PSAO, 340B Admin, Chargebacks/Rebates Ops) (CRAOAHAK)

akta.pro secondary industry

Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC) (HLAGAHAM)

Keywords

• Active pharmaceutical ingredients
• Pharmaceutical distribution
• Drug registration services
• API import trading
• Pharmaceutical raw materials

Headquarters

HQ city

Shanghai

HQ country

China

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Supply Chain, Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

1. API Distribution and Trading: Dingkang Pharmaceutical generates revenue by sourcing and distributing Active Pharmaceutical Ingredients (APIs) from international manufacturers (primarily from India, France, Japan, Israel, South Korea) to domestic Chinese pharmaceutical companies. The company acts as an authorized representative for major Indian API brands including Divis, IPCA, Piramal, Ami Lifescience, and Virupaksha.
2. Drug Registration Services: The company provides professional drug registration services helping pharmaceutical manufacturers navigate the regulatory approval process for APIs and finished dosage forms in China, including eCTD submission services.
3. Imported Generic Drug Supply: Dingkang supplies imported generic active pharmaceutical ingredients that have received approval for import, providing compliant raw materials for pharmaceutical formulation enterprises.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels3 records

Core offering

Dingkang Pharmaceutical is a Shanghai-based pharmaceutical company that imports, registers, and distributes Active Pharmaceutical Ingredients (APIs) for Chinese pharmaceutical manufacturers. The company sources APIs from international manufacturers (including Indian API brands Divis, IPCA, Piramal, Ami Lifescience, and Virupaksha) and supplies them with full USDMF/CEP certifications and CDMF registrations across cardiovascular, antihistamine, anti-inflammatory, antifungal, neurological, and weight management therapeutic categories. It also provides professional drug registration services, including eCTD V4.0 regulatory submissions, to help domestic formulators secure Chinese market authorization.

Product overview

Dingkang Pharmaceutical is a pharmaceutical API importer and distributor based in Shanghai, China. The company operates as a unified platform offering two core product categories: (1) Active Pharmaceutical Ingredients (APIs) including registered products with completed CDMF approvals and products in active registration process, covering cardiovascular drugs (Amlodipine Besylate, Atenolol, Bisoprolol Fumarate, Valsartan, Metoprolol Tartrate), antihistamines (Desloratadine, Loratadine), anti-inflammatory/analgesic agents (Nabumetone, Ketoconazole, Fluconazole), neurological medications (Levetiracetam, Pregabalin, Quetiapine Fumarate), and weight management products (Orlistat); and (2) Professional services including drug registration consulting, eCTD V4.0 submission support, and Indian API import services. APIs are sourced from India, France, Japan, Israel, and South Korea with USDMF and CEP certifications.

Differentiator

Problem solved

Functional benefit

Products and services

• Amlodipine Besylate API Calcium channel blocker API used for treatment of hypertension and coronary heart disease. Registered product with CDMF Number Y20200000985, supplied to Chinese pharmaceutical manufacturers.
• Atenolol API Beta blocker API for cardiovascular applications. Registered product with CDMF Number Y20170001479, supplied to Chinese pharmaceutical manufacturers.
• Bisoprolol Fumarate API Selective beta-1 receptor blocker API used for hypertension, angina pectoris, and heart failure. Registered product with CDMF Number Y20170001028, supplied to Chinese pharmaceutical manufacturers.
• Valsartan API Angiotensin II receptor antagonist (ARB) API for hypertension and heart failure treatment and core component of Entresto. Registered product with CDMF Number Y20200000337, supplied to Chinese pharmaceutical manufacturers.
• Nabumetone API Non-steroidal anti-inflammatory and analgesic API with stable performance and low side effects. New arrival product suitable for various pharmaceutical preparations.
• Orlistat API Weight management API that inhibits intestinal lipase to block dietary fat absorption. Used in capsules, dietary supplements, and functional pharmaceutical preparations.
• Sitagliptin Phosphate API DPP-4 inhibitor API for Type 2 diabetes treatment. Registered product with CDMF Number Y20210000498, supplied to Chinese pharmaceutical manufacturers.
• Metoprolol Tartrate API Beta-1 selective blocker API for cardiovascular conditions. Approved for import in February 2025. CDMF Number Y20220000474.
• Dextromethorphan Hydrobromide API Central nervous system antitussive agent that inhibits the medulla oblongata's cough center. Used for dry coughs from upper respiratory infections, bronchitis. CDMF Number Y20170001275.
• Desloratadine API Second-generation antihistamine API for allergic reactions. Active metabolite of loratadine with longer half-life. Registered product with CDMF Number Y20170000139.
• Quetiapine Fumarate API Atypical antipsychotic API for schizophrenia and bipolar disorder treatment. CDMF Number Y20170000343.
• Levetiracetam API Antiepileptic API for seizure treatment. CDMF Number Y20180001576.
• Fluconazole API Synthetic triazole antifungal API effective against a broad range of fungal infections. CDMF Number Y20190009946.
• Ketoconazole API Antifungal API that disrupts ergosterol production in fungal cells. Available as cream, shampoo, and oral tablets. CDMF Number Y20200001119.
• Itopride Hydrochloride API Prokinetic API that promotes gastrointestinal motility and inhibits acetylcholinesterase for treating bloating, belching, and loss of appetite.
• Carbidopa API Peripheral decarboxylase inhibitor API used in combination with levodopa for Parkinson's disease treatment. CDMF Number Y20190000314.
• Vecuronium Bromide API Medium-efficacy non-depolarizing neuromuscular blocking drug for muscle relaxation in surgical anesthesia.
• Lemaitamide (Remetidine) API API targeted at the sleep health market, positioned for pharmaceutical and healthcare channel partners nationwide.
• Drug Registration Services Professional drug registration services for Chinese pharmaceutical manufacturers, including dossier preparation, regulatory submission, eCTD format compliance, and tracking coordination with Chinese regulatory agencies (NMPA/CDE). Core team has hands-on experience in drug regulatory registration compliant with ICH international standards.
• Indian API Import Services Sourcing and importing high-quality APIs from India including Divis, IPCA, Piramal, Ami Lifescience, and Virupaksha, all backed by USDMF and CEP certifications with GMP-compliant quality standards.

Named customers2 records

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Six partnerships are on record, tiered core.

• Divis (India)coreStrategic or Co-development PartnerDivis is an Indian pharmaceutical company and one of the top API brands represented by Dingkang Pharmaceutical in China. Dingkang serves as the representative and supplier for Divis APIs in the Chinese market.
• IPCA (India)coreStrategic or Co-development PartnerIPCA is an Indian pharmaceutical manufacturer whose APIs are represented and supplied by Dingkang Pharmaceutical in China. All products are backed by USDMF and CEP certifications.
• Piramal (India)coreStrategic or Co-development PartnerPiramal is an Indian pharmaceutical company and top API brand represented by Dingkang in the Chinese market, providing compliant pharmaceutical raw materials.
• Ami Lifescience (India)coreStrategic or Co-development PartnerAmi Lifescience is an Indian pharmaceutical company whose APIs are sourced and distributed by Dingkang Pharmaceutical in China.
• Virupaksha (India)coreStrategic or Co-development PartnerVirupaksha is an Indian pharmaceutical manufacturer and API brand represented by Dingkang Pharmaceutical in China.
• Domestic Pharmaceutical Companies (600+)coreChannel Partner/ Reseller/ DistributorDingkang has established partnerships with over 600 domestic pharmaceutical companies in China, serving as their API supplier and providing compliance procurement solutions.

Scale indicators6 records

Recent moves8 records

Expansion highlights6 records

Broad incumbents

• Sinopharm Group: State-owned pharmaceutical and healthcare distribution leader in China, with API and finished drug distribution. Comparable as China's dominant pharma distribution incumbent, though substantially larger and broader than Dingkang's API-focused intermediary business.
• Jiangsu Hengrui Pharmaceuticals: China's largest innovative pharma company with a significant API and formulation business serving domestic and export markets. Comparable as a Chinese-headquartered broad pharma competitor that includes APIs and finished formulations overlapping Dingkang's distribution categories.
• Shanghai Pharmaceuticals Holding: Largest Shanghai-based pharmaceutical distributor with API and finished-drug distribution businesses. Comparable as a broad incumbent operating China-wide pharmaceutical distribution, but with much wider portfolio and stronger financing than Dingkang's focused API intermediary model.
• CSPC Pharmaceutical Group: Vertically integrated Chinese pharma major with manufacturing, distribution, and innovation segments including APIs serving domestic formulators. Comparable as a broader incumbent that competes for the same Chinese pharma distribution channels, but at much larger scale and broader product scope.

Emerging players

• PharmaBlock Sciences (Nanjing): China-based chemistry services and small-molecule development company providing building blocks, intermediates, and reference standards serving pharma customers. Comparable to Dingkang as a smaller, specialized China-headquartered pharma chemical services/intermediation provider focused on domestic formulators.
• Hunan Er-Kang Pharmaceutical: Chinese pharmaceutical company with API manufacturing and distribution across multiple therapeutic categories. Comparable to Dingkang as a smaller, China-based pharma business that combines API supply with domestic distribution, albeit at a different scale.
• Hangzhou Tigermed Consulting (Tigermed): China's leading clinical CRO and drug regulatory consulting group providing registration and clinical development services to pharma clients. Comparable to Dingkang's drug registration service line as a Chinese domestic regulatory/compliance services provider for pharmaceutical customers.

Direct peers

• Zhejiang Huahai Pharmaceutical: Leading Chinese manufacturer of cardiovascular and CNS active pharmaceutical ingredients, including Valsartan and other ARBs that overlap directly with Dingkang's distribution portfolio. Comparable as a Chinese-headquartered API supplier/distributor competing for the same Chinese formulation customers.
• Apeloa Pharmaceutical: One of China's largest API manufacturers with broad therapeutic coverage (cardiovascular, anti-infective, oncology) and international supply linkages. Comparable to Dingkang as a China-based API business covering similar therapeutic categories with both domestic and export distribution.
• Hisun Pharmaceutical: Chinese API and finished-dose manufacturer with large-scale international supply operations and a portfolio overlapping cardiovascular and specialty therapeutic areas. Comparable to Dingkang as a Chinese pharmaceutical company selling APIs to domestic and export channels.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/dingkang-pharmaceuticals-ltd-

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Dingkang Pharmaceutical